Heron Therapeutics, Inc. HRTX R2KR3KPHARMA
Company Overview
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Why Investors Should Care
Revenue has grown at a 70.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $154.90M (+7.4% YoY); net profit $-20.20M.
- Trailing 12 Months Year-on-year growth — revenue -10.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 70.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 70.40% |
| 1 Year: | -10.80% |
Stock Price Performance
| 1 Year: | -75.71% |
| 6 Months: | -64.95% |
| 3 Months: | -20.93% |
| 1 Month: | -32.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 70.4% over 5 years.
CONS
- Trading 77.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HRTX Heron Therapeutics, Inc. R2KR3KPHARMA | 0.34 | -1.89 | $64.35M | 0.00% | -1.59% | -140.90% | 70.40% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 3.63M | 8.51M | 8.57M | 10.05M | 11.57M | 17.28M | 19.79M | 28.84M | 31.60M | 36.66M | 42.62M | 35.08M | 25.40M | 22.67M | 19.96M | 20.61M | 20.02M | 22.44M | 23.23M | 23.46M | 27.63M | 26.56M | 29.61M | 31.76M | 31.43M | 34.67M | 36.02M | 32.81M | 38.90M | 37.20M | 38.21M | 34.71M | 37.67M |
| Gross Profit | - | - | - | - | - | - | 1.24M | 2.45M | 7.50M | 7.52M | 8.71M | 8.43M | 12.05M | 12.21M | 17.27M | 16.64M | 23.07M | 25.43M | 19.21M | 14.78M | 13.66M | 12.79M | 11.21M | - | - | - | - | - | 11.84M | 12.76M | 11.60M | 13.23M | 26.23M | 25.51M | 23.35M | 30.45M | 27.34M | 26.30M | 24.07M | 26.09M |
| Operating Income | -23.01M | -22.49M | - | -33.31M | -43.07M | -47.73M | - | -49.30M | -42.05M | -41.31M | - | -51.99M | -38.85M | -41.78M | -51.31M | -64.70M | -51.78M | -34.85M | -59.36M | -52.73M | -55.75M | -58.38M | -61.30M | -52.11M | -60.47M | -51.71M | -62.92M | -49.50M | -41.88M | -33.06M | -42.40M | -24.93M | -4.80M | -6.45M | -4.46M | 3.15M | -1.64M | -4.09M | -4.76M | -2.04M |
| Net Income | -23.11M | -22.67M | -31.24M | -33.45M | -43.23M | -48.51M | -47.96M | -50.33M | -42.80M | -41.87M | -62.49M | -52.27M | -38.67M | -38.35M | -49.56M | -63.01M | -50.22M | -33.59M | -57.92M | -51.58M | -55.19M | -58.23M | -62.28M | -52.61M | -61.02M | -52.41M | -63.89M | -56.36M | -41.91M | -32.77M | -42.06M | -25.01M | -3.16M | -9.23M | -4.85M | 2.63M | -2.38M | -17.50M | -8.11M | -5.49M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.62 | -0.51 | -0.63 | -0.55 | -0.38 | -0.27 | -0.35 | -0.17 | -0.02 | -0.06 | -0.03 | 0.01 | -0.02 | -0.10 | -0.04 | -0.03 |
| R&D Expense | 16.18M | 14.24M | 16.26M | 16.09M | 27.29M | 30.24M | 29.50M | 33.38M | 28.60M | 28.84M | 47.76M | 39.56M | 30.16M | 30.42M | 39.89M | 42.97M | 41.42M | 34.71M | 48.28M | 36.89M | 44.00M | 49.18M | 44.45M | 38.12M | 35.23M | 28.59M | 42.07M | 28.83M | 25.55M | 8.84M | 13.21M | 9.29M | 4.61M | 4.43M | 4.46M | 2.28M | 2.93M | 3.47M | 2.38M | 2.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 1.28M | 30.77M | 77.47M | 145.97M | 88.64M | 86.35M | 107.67M | 127.04M | 144.28M | 154.90M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.80M | 61.94M | 105.64M | 113.56M |
| Operating Income | -10.24M | -9.93M | -11.06M | -23.83M | -54.46M | -74.56M | -96.92M | -170.91M | -194.56M | -183.94M | -210.69M | -228.16M | -217.83M | -174.66M | -110.61M | -11.53M | -2.54M |
| Net Income | -10.03M | -7.35M | -11.81M | -23.35M | -55.28M | -76.37M | -97.59M | -173.14M | -197.48M | -178.84M | -204.75M | -227.28M | -220.68M | -182.02M | -110.56M | -13.58M | -20.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 |
| R&D Expense | 7.80M | 7.26M | 8.21M | 15.17M | 32.52M | 54.83M | 61.18M | 103.12M | 138.58M | 140.03M | 167.38M | 174.53M | 130.82M | 82.70M | 39.13M | 16.68M | 12.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.91M | 19.45M | 55.97M | 75.94M | 76.68M | 137.84M | 67.48M | 234.31M | 462.18M | 512.78M | 353.56M | 305.71M | 250.95M | 222.51M | 233.15M | 255.88M |
| Total Equity | - | 6.80M | 1.32M | 15.75M | 51.82M | 68.94M | 63.06M | 118.11M | -21.25M | 131.14M | 370.16M | 403.83M | 236.49M | 77.57M | 13.57M | -33.97M | -33.65M | 14.33M |
| Cash & Equivalents | 9.97M | 7.59M | 2.11M | 17.97M | 53.51M | 72.29M | 72.67M | 75.18M | 13.41M | 144.58M | 31.84M | 71.90M | 105.14M | 90.54M | 15.36M | 28.68M | 25.80M | 28.65M |
| Total Liabilities | - | - | 1.59M | 3.69M | - | - | - | 19.73M | 88.73M | 103.17M | 92.02M | 108.95M | 117.06M | 228.14M | 237.38M | 256.48M | 266.80M | 241.54M |
| Current Liabilities | - | - | 1.56M | 3.69M | 4.15M | 6.99M | 13.62M | 19.73M | 38.73M | 103.17M | 92.02M | 96.70M | 102.50M | 71.06M | 82.36M | 79.69M | 91.46M | 96.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.00M | -5.48M | -7.72M | -17.01M | -40.76M | -60.28M | -78.53M | -134.10M | -170.30M | -191.81M | -124.58M | -184.82M | -203.35M | -146.91M | -58.79M | -22.53M | -27.59M |
| Investing Cash Flow | 612.00K | -78.00K | -513.00K | -972.00K | -1.69M | -1.44M | -56.96M | 14.88M | 7.74M | -278.55M | -21.78M | 208.96M | 32.73M | -3.32M | 18.00M | 18.71M | 16.01M |
| Financing Cash Flow | 8.01M | 77.00K | 24.10M | 53.51M | 61.23M | 62.11M | 137.99M | 57.45M | 293.73M | 357.61M | 186.43M | 9.11M | 156.03M | 75.06M | 54.11M | 940.00K | 14.43M |
| Capital Expenditure | -2.00K | -78.00K | -513.00K | -972.00K | -1.69M | -1.44M | -1.09M | -3.13M | -2.55M | -9.17M | -7.15M | -6.81M | -3.02M | -1.82M | -1.54M | -1.71M | -317.00K |
| Free Cash Flow | -11.00M | -5.56M | -8.23M | -17.98M | -42.45M | -61.72M | -79.61M | -137.23M | -172.85M | -200.98M | -131.73M | -191.63M | -206.38M | -148.74M | -60.33M | -24.23M | -27.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.0% | 48.8% | 73.2% | 73.3% |
| Operating Margin % | - | - | - | - | - | - | - | -13,363.2% | -632.4% | -237.4% | -144.3% | -257.4% | -252.3% | -162.2% | -87.1% | -8.0% | -1.6% |
| Net Margin % | - | - | - | - | - | - | - | -13,537.4% | -641.9% | -230.8% | -140.3% | -256.4% | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% |
| ROE % | -147.6% | -558.2% | -75.0% | -45.1% | -80.2% | -121.1% | -82.6% | 814.8% | -150.6% | -48.3% | -50.7% | -96.1% | -284.5% | -1,341.2% | 325.4% | 40.4% | -140.9% |
| ROCE % | - | -735.3% | -70.2% | -46.0% | -79.0% | -118.2% | -82.1% | -594.5% | -148.4% | -49.7% | -50.6% | -90.9% | -92.8% | -103.6% | -77.5% | -8.1% | -1.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 15.83% | 30.05M | $9.81M |
| 2 | Clearline Capital, LP | 6.00% | 11.38M | $3.72M |
| 3 | Blackrock Inc. | 5.56% | 10.55M | $3.45M |
| 4 | Velan Capital Investment Management LP | 4.61% | 8.75M | $2.86M |
| 5 | Vanguard Capital Management LLC | 4.10% | 7.78M | $2.54M |
| 6 | Tejara Capital Ltd | 3.43% | 6.51M | $2.13M |
| 7 | Tang Capital Management, LLC | 3.29% | 6.25M | $2.04M |
| 8 | Geode Capital Management, LLC | 2.25% | 4.27M | $1.39M |
| 9 | Millennium Management Llc | 2.14% | 4.07M | $1.33M |
| 10 | JW Asset Management, LLC | 1.98% | 3.75M | $1.23M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HRTX
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPNU9ZREtILTYzVk54bzlLV1VwVk9FZzVIeDVhdlY5bUxIbkF3QVFGTGFET0NobDdUS2lxcFA4cllHY2RVSjRNdVQzMEdydnl1VWd1anRsc1o0YU1vaVotUTVZdmZKWEt0T2xxZTdRMnNadmYxM24wMGZLWHBIaFdQcTg2a3diRFZyajJ1VG…
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNZXFjWTB0Sy1WUVNfaWZaUlJEWFJKXzF2YnBUcEg1Wjl4ZEhiOFQ2MFRyTzVvTHpDejN3U3RHM24td0piSll0aDZ5blJyMGNmU2c2M1h5cE1SempuUUgzcHotNjVPUDNBcHFPM3VBSHFsVkdHaFJjTEJJSGVUNG5ZRmtic08yYXRrX0N5Zj…
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOZ2VWWnZIZ0pqODNta3RZTFp4TXgwck5SZVZwQzFTUG1QLXlHVlFrZndUWDY2ODZVOGR0amJuQzIzVkJfT01vTzhHRjBTMXBrM2ZmVlZpZTM3MDJhc2lzS3EzYTVRLVlTSl9EUmNnXzZtazlKQUVVb3pPRXZ1QVNmZzdhakRmT1RKbGlOU0…
HERON THERAPEUTICS Q2 2026 Earnings Preview: Recent $HRTX Insider Trading, Hedge Fund Activity, and More - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOdTQ4cjdGVTBrb242X1cyUHlrWGNHTjJPRnFwelhTR3FwSGZpaTNNX1hVakpwUlg5VUl1VUxjdlo5cjRvbVh5bVBtcHdJRlU1NXZxRnV4RnhWRG90SUlRN2FUQ19hc3BIWnV3dzBOSVU0TldRVFpKZVFqN2paMmRIa196anp2ODBCaGVsZH…
HRTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1kWmlLS2JScmROaDlFUDc1bmdUbVh0UXdVR05LMURyMWtTa3RsYXo4NC10RnM4dXN2Q28ySDR5dlVkc3hXSGRZb0RTX2NCWW9yTy1ieDNkN2FvenBVNTJFV29lSDZISEVtYVVRelVwY3U1UEdieTZvVXd3?oc=5" target="_blank">HRT…
HRTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1zQjFoYlAzSXR2eGVQWHBNVi1sSG1nazg4cGlxSUFoNkFYLVRmWVZXMk5zUTZZLXg2ZjE4eU5pRk83ZmNSaVE?oc=5" target="_blank">HRTX</a> <font color="#6f6f6f">Finviz</font>…
HRTX — Frequently Asked Questions
What is the current share price of Heron Therapeutics, Inc. (HRTX)?
As of 2026-09-07 16:24 PDT, Heron Therapeutics, Inc. (HRTX) trades at $0.34 on NasdaqCM. Its 52-week range is $0.30 to $1.49.
What is the market capitalisation of HRTX?
Heron Therapeutics, Inc. (HRTX) has a market capitalisation of $64.35M on NasdaqCM.
What is the P/E ratio of HRTX?
HRTX trades at a trailing price-to-earnings (P/E) ratio of -1.89. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 11.41.
What is the return on equity (ROE) of HRTX?
HRTX has a return on equity (ROE) of -140.90%. Its return on capital employed (ROCE) is -1.59%.
Is HRTX a good stock to buy?
This page provides a data-driven analysis of Heron Therapeutics, Inc. (HRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.